Last reviewed · How we verify

NCT04277429: THERESE

HFpEF and 2-year Mortality of COPD Patients

Status unknown Last updated 2 November 2022
What this trial tests

trial testing Cardiac function assessment in Chronic Obstructive Pulmonary Disease in 150 participants. Status unknown.

Timeline
1 July 2020
Primary endpoint
1 April 2025
1 April 2025

Quick facts

Lead sponsorUniversity Hospital Olomouc
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment150
Start date1 July 2020
Primary completion1 April 2025
Estimated completion1 April 2025
Sites2 locations across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Olomouc

Who can join

Adults 40 to 80, any sex, with Chronic Obstructive Pulmonary Disease or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was designed to assess potential relationship between heart failure with preserved ejection fraction and 2- year mortality of patients with chronic obstructive pulmonary disease

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other University Hospital Olomouc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04277429.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing